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TECHNICAL NOTE
True lumen re-entry devices facilitate subintimal
angioplasty and stenting of total chronic
occlusions: Initial report
Donald L. Jacobs, MD, Raghunandan L. Motaganahalli, MD, Daniel E. Cox, MD,
Catherine M. Wittgen, MD, and Gary J. Peterson, MD, St Louis, Mo
Objective: The acute technical failure of endovascular treatment of chronic total occlusions (CTOs) is most often due to
the inability to re-enter the true lumen after occlusion is crossed in a subintimal plane. This study reports our initial
experience with true lumen re-entry devices in the treatment of CTOs.
Methods: Patients with treatment of CTOs were identified from our vascular registry. All patients in whom the Pioneer
catheter or the Outback catheter were used were also identified from a prospectively maintained separate database of cases
in which true lumen re-entry devices were used. We used procedural data from the prospective database and reviewed the
medical records. Lesion character and location, access type, location of true lumen re-entry, stent usage, procedural times,
and complications, were tabulated.
Results: From August 2003 to December 2004, endovascular techniques were used to treat 87 CTOs in 58 iliac and 29
superficial femoral arteries. In 24 (26%), the true lumen could not be re-entered by using standard catheter and wire
techniques. The true lumen was not initially re-entered in 20 (34%) of 58 of treated iliac CTOs and four (13%) of 29 of
treated superficial femoral artery CTOs (73% TASC C and D lesions). Intravascular ultrasound-guided true lumen
re-entry using the Pioneer catheter (21 CTOs), or fluoroscopic-guided true lumen re-entry using the Outback catheter
(3 CTOs) was successful in achieving true lumen re-entry in all cases at the location desired. Total time of re-entry
catheter manipulation required to achieve re-entry was <10 minutes and was routinely accomplished in <3 minutes. All
occlusions were stented. No cases were converted to open repair. Bleeding from the recanalization and angioplasty site
occurred in four patients (15%). It was controlled with use of covered stents in two cases, and resolved after placement of
uncovered stents in the other two. No significant bleeding occurred at the sites of true lumen re-entry needle deployment.
All occlusions treated with true lumen re-entry devices remain clinically patent at a mean follow-up of 5.8 months.
Conclusions: Endovascular treatment of chronic total occlusions is often limited by the inability to re-enter the true lumen
after subintimal crossing of the occluded segment. This occurs more commonly with treatment of iliac occlusions than in
superficial femoral artery occlusions. True lumen re-entry catheters are very effective at gaining wire passage back to the
true lumen and facilitating successful endovascular treatment of chronic total occlusions that would otherwise require
open bypass. ( J Vasc Surg 2006;43:1291-6.)Endovascular treatment of chronic total occlusions
(CTOs) is increasing. Themost commonmethod for cross-
ing occlusions uses hydrophilic wires and catheters, often, if
not always, in the subintimal plane for a portion of the
occlusion. Although recanalization through a CTO is often
challenging, the primary limitation to successful treatment
of CTOs is reported to be the failure to re-enter the true
lumen after subintimal crossing of the occlusion.1-3 This
may be an increasingly important limitation to procedural
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An additional limitation in some cases is that the true
lumen re-entry is not achieved until subintimal passage to a
site significantly remote from the level of vessel lumen
patency, causing subintimal angioplasty or stenting, or
both, to extend beyond the occluded segment. This may
put additional branch points, collaterals, and potential “no-
stent zones,” such as the common femoral and popliteal
arteries adjacent to occluded segments, at risk of the com-
plications of angioplasty and stenting due to the potential
inaccuracy of the point of true lumen re-entry.
Devices that have been developed to facilitate true
lumen re-entry offer the potential to overcome this limita-
tion to the acute success of treating CTOs. In this report,
we describe our initial experience with true lumen re-entry
devices in the endovascular treatment of iliac and superficial
femoral artery CTOs.
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All patients who had endovascular treatment of iliac
and superficial femoral artery CTOs during the study pe-
riod were identified on an intention-to- treat basis from our
vascular registry. All patients in whom the Pioneer catheter
(Medtronic, Inc, Minneapolis, Minn) or the Outback cath-
eter (LuMend, Redwood City, Calif acquired by Cordis
Corporation, Miami Lakes, Florida) was used in the treat-
ment of their CTO were identified from a prospectively
maintained separate database of all cases in which true
lumen re-entry devices were used. Institutional Review
Board approval of the data collection and analysis in this
group of patients was obtained.
A retrospective reviewwas conducted of this prospectively
collected data, and the clinical record and follow-upof all cases
was also reviewed. Indication for intervention, lesion character
as defined by the TransAtlantic InterSocietal Consensus
(TASC) classification,4 lesion location, access type, location of
true lumen re-entry, stent use, procedural times, anesthesia,
and complications, were tabulated. Clinical patency was de-
fined by symptomatic relief of rest pain or improvement in
claudication,maintenance of a palpable pulse, and the increase
of0.1 in ankle/brachial index (ABI).
Follow-up intervals were 1 month, 6 months, and
annually thereafter. Ultrasound imaging at follow-up was
routinely done for femoral interventions at the same inter-
vals, but routine follow-up imaging was not done for iliac
interventions.
Technique. Arterial access was typically retrograde
femoral for iliac occlusions and contralateral retrograde
femoral for femoral occlusions. Less frequent were con-
tralateral retrograde common femoral access for external
iliac occlusions and antegrade common femoral access for
superficial femoral occlusions. Brachial access was not used
for iliac or femoral occlusions. Open access was used when
common femoral occlusive disease required open repair or
endograft repair was planned of an infrarenal AAA with an
associated iliac occlusion. All patients were systemically
heparinized before the CTO was manipulated.
CTOs of the iliac and femoral arteries were crossed
with combinations of a hydrophilic 0.035-inch Glidewire
(Terumo, Somerset, NJ) or a 0.035-inch Acqwire (ev3,
Plymouth, Minn) guidewire and a 3F Glidecath hydro-
philic catheter (Terumo). Additional support with sheaths
or guidewires, or both, was used as needed for access as well
as for pushability for crossing occlusions. It is important to
note that retrograde iliac recanalization was routinely per-
formed with the direct backup of an ipsilateral femoral
sheath or its dilator, or both.
Femoral occlusions were routinely crossed with the
backup of a 7F 55-cm sheath placed from the contralateral
femoral artery over the aortic bifurcation with the tip into the
femoral artery as close to the occlusion as possible. Occasion-
ally, balloon angioplasty of a portion of the occlusion was
required to facilitate crossing the remaining occlusion.
Additionally, the back end of the hydrophilic wire was
occasionally used to cross short, resistant segments of aCTO. No lasers or mechanical dissector devices were used
to cross occlusions.
No standard technique was used to place the wire
intentionally subintimal; however, subintimal passage was
thought to be present in almost all of the CTO crossings
and was obvious in all cases requiring the use of true lumen
re-entry devices. Successful true lumen re-entry was defined
as re-entry 2 cm of the optimal angiographically defined
target vessel beyond the occlusion without compromise of
significant collaterals or branches. Iliac artery occlusions
were routinely stented with balloon-expandable stents in
the common iliac artery.
If the wire was not in the true lumen after the CTO was
crossed, attempts to gain access to the true lumen with cath-
eter wire manipulations were routinely tried, with additional
catheters, wires, guides, and balloons used to gain access to
the true lumen. Gentle contrast injections in the dissection
plane were used to define any communication to the true
lumen. If access to the true lumen failed after 10 minutes of
manipulation, a true lumen re-entry device was used.
The Pioneer catheter (Fig 1) is a 7F intravascular ultra-
sound (IVUS) catheter with a solid-state transducer that
uses the In-Vision IVUS system (Volcano Therapeutics, Ran-
cho Cordova, Calif). The catheter has a monorail 0.014-inch
delivery lumen. The 0.035-inch wire used to cross the
occlusion is exchanged for a 0.014-inch wire to deliver the
Pioneer catheter into the dissection plane at the point of
desired true lumen re-entry.
The Pioneer has a hypo-tube through the lumen with a
curved retractable nitinol needle distally. The curved needle
tip is advanced in a controlled fashion to extend up to a
distance of 7 mm and projects away from the IVUS
Fig 1. Pioneer intravascular ultrasound true lumen re-entry cath-
eter with needle deployed.catheter at the 12 o’clock position on the IVUS image.
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and color-flow imaging of the catheter. The catheter is
rotated to place the true lumen target at 12 o’clock on the
IVUS image and the needle is deployed (Fig 2).
An exchange length extra-support 0.014-inch guide-
wire is then passed from the end of the catheter through the
needle and into the true lumen. The needle is retracted, and
then the Pioneer catheter is withdrawn, leaving the extra-
support wire traversing the occlusion and into the true
lumen beyond. The 0.014-inch guidewire was typically
then exchanged for a 0.035-inch wire to facilitate iliac or
superficial femoral artery (SFA) angioplasty and stenting.
Occasionally, the intima traversed at the point of true
lumen re-entry must be dilated by using a 0.014-inch
balloon (4- or 5-mm diameter) to enable a catheter to pass
to exchange for the 0.035-inch wire.
The Outback catheter is a 5F multipurpose type
angled guide catheter with an integral hypo-tube ending
in a curved nitinol needle that can be advanced or
retracted from the end of the catheter to penetrate from
the dissection plane to the true lumen (Fig 3). The
needle is retracted and the device delivered over the wire
to the point of true lumen re-entry. The multipurpose
angle of the catheter is manipulated to point the end
toward the true lumen by fluoroscopic guidance. The
needle is then advanced to deploy it through the intima
to the true lumen. A 0.014-inch extra-support wire is
then advanced into the true lumen (Fig 4). The Outback
catheter is then removed and the wire exchanged, with or
without 0.014-inch balloon dilation as noted, for the
0.035-inch wire that is used to perform iliac and femoral
Fig 2. Pioneer catheter intravascular ultrasound image with cath-
eter in the dissection plane of an iliac above an occlusion traversed
subintimally.angioplasty and stenting. In cases that required stentingto within 2 cm of the inguinal ligament, self-expanding
nitinol stents were used in external iliac occlusions after
pre-dilating.
Minor extravasation of contrast after angioplasty or
stenting is treated by temporary balloon occlusion and
re-evaluation. Persistent or large extravasations are treated
with balloon inflation until preparations are made for the
delivery of a Fluency covered stent (CR Bard Inc, Murray
Hill, NJ). By not using a sheath, the Fluency stents were
able to be placed without increasing the arterial puncture
size. The Fluency delivery catheter is passed over the wire
after quickly deflating the occluding balloon and removing
the balloon and sheath. After removal of the covered stent
delivery catheter, the 7F or 8F sheath that was originally
used can be replaced and is hemostatic at the puncture site.
All femoral artery occlusions were angioplastied and
provisionally stented with self-expanding nitinol stents.
Routine completion angiography was done to evaluate for
distal embolization, thrombosis, or dissection after all in-
terventions were complete.
All patients were treated with aspirin. All patients with
infrainguinal interventions were administered clopidogrel
(75 mg/day) for a minimum of 6 weeks.
RESULTS
During a 16-month period from August 2003 to De-
cember 2004, 127 iliac and 76 femoral arteries were treated
with endovascular techniques, of which 87 (43%) were
CTOs. Fifty-eight (46%) of the 127 iliac lesions and 29
(38%) of the 76 femoral lesions were CTOs. All CTOs in
the iliac and femoral vessels were successfully treated during
the study period on an intention-to-treat basis.
In 24 (28%) of 87 of the CTOs treated, the true lumen
could not be re-entered by using standard catheter and wire
techniques, and a true lumen re-entry catheter was used. A
Fig 3. Outback catheter with needle retracted (A) and deployed
(B).true-lumen re-entry catheter was used in 20 (34%) of 58 of
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required use of a true lumen re-entry catheter.
The Pioneer IVUS-guided true lumen re-entry catheter
was used in 21 vessels in 20 patients (18 iliac arteries and 3
SFAs). The Outback fluoroscopic-guided true lumen re-
entry catheter was used in three vessels in two patients (2
iliac arteries and 1 SFA). Two patients (one with each
catheter type) required true lumen re-entry bilaterally for
bilateral iliac artery occlusions.
Lesion characteristics were 7 unilateral common iliac
occlusions, 6 total common and external iliac occlusions, 4
bilateral common iliac occlusions, 3 unilateral external iliac
occlusions, 3 long femoral occlusions10 cm, and 1 short
3-cm femoral occlusion. Mean length of the occlusions
were 4.1 cm for the common iliac artery occlusions, 8.0 cm
for the external iliac occlusions, and 15.3 cm for the con-
tiguous common and external iliac occlusions. Overall, iliac
artery occlusion length was 8.1 cm. The SFA occlusions
were 3 cm, 12 cm, 15 cm, and 24 cm in length for a mean
Fig 4. Outback catheter with needle (arrow) and wire deployed
into true lumen of femoral artery distal to occlusion.femoral occlusion length of 13.5 cm.T h e Table lists the TASC classification for the 22 patients.
Two patients had total iliac artery occlusions treated at the
time of placement of a bifurcated aortic stent-graft for infra-
renal aortic aneurysms via open femoral access. Two addi-
tional patients had open common femoral artery access for
treatment of significant common femoral artery disease. All
other cases were done percutaneously.
The study group included 24 CTOs in 22 patients (18
men and 4 women, mean age 61). Indication for interven-
tion in these 22 patients was rest pain or tissue loss in 12
patients and severe claudication in 10. True lumen re-entry
was successful in all cases at the level of vessel reconstitution
within 2 cm of the optimal angiographically defined target
vessel beyond the occlusion without compromise of signif-
icant collaterals or branches. Total time of re-entry catheter
manipulation required to achieve re-entry was10 minutes
andwas routinely accomplished in3minutes.Overall mean
fluoroscopy time was 38 minutes, with the first four cases
averaging 52 minutes of fluoroscopy and the last four cases
only averaging 26 minutes of fluoroscopy. All occlusions
were stented. No cases were converted to open repair.
No embolic complications occurred in the patients
treated with true lumen re-entry devices. The only complica-
tions that occurred were bleeding at the site of recanalization
and angioplasty in four patients (18%). All bleeding complica-
tions weremanifested at the time of the procedure. Neither of
the patients with an associated AAA had bleeding complica-
tions. Indeed, all four instances of bleeding occurred in cases
of iliac arteryCTO recanalization not associatedwith anAAA,
making the bleeding complication rate for this subset of
patients 25%. Bleeding was controlled with use of covered
stents in two cases and was resolved after placement of uncov-
ered stents in the other two. None of these patients had
transfusions or prolonged length of stay. It is important to
note that no significant bleeding occurred at the sites of true
lumen re-entry needle deployment.
All occlusions treated with true lumen re-entry devices
demonstrated clinical success at a mean follow-up of 5.8
months (range, 1 to 17 months). All patients undergoing
iliac artery reconstructions had palpable femoral pulses and
all with SFA reconstructions had palpable popliteal pulses at
follow-up. All patients showed an increase of 0.1 in their
ABI. ABIs for the 15 patients who completed 6-month
follow-up showed a mean pre-procedure ABI of 0.58 and a
Table. TransAtlantic InterSocietal Consensus (TASC)
classification of the 22 patients who required true lumen
re-entry devices
TASC B TASC C TASC D
Iliac 5 3 10
Femoral 1 0 3
Total 6 3 13mean 6-month ABI of 0.97.
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The ability to treat CTOswas initially limited primarily by
the failure to cross the occlusion, then by the failure of balloon
angioplasty. With the development of stents to treat failed
angioplasty, the primary cause for acute procedural failure in
the treatment of CTOs became the inability to cross back into
the true lumen after crossing the occluded segment.1-3 To
overcome this technical challenge, two catheters were devel-
oped to allow for passage of a needle and guidewire across the
intima distal to the occlusion. Two other case series (one with
seven CTOs and another with five CTOs) and one single case
report on using these true lumen re-entry catheters have been
reported.3,5,6 To our knowledge, this report is the first to
analyze the use of these catheters in a consecutive series of
CTO recanalizations.
The first catheter, initially released in August 2002, was
the Crosspoint catheter from TransSonics, later acquired by
Medtronic, Inc, and renamed the Pioneer catheter (Fig 1).
The IVUS integrated to the device allows for real-time imag-
ing at the time of needle deployment. In addition to showing
the intima and true lumen, the color flow capability of IVUS
imaging adds an additional confirmation of the patency of the
vessel at the point of needle deployment.
The presence of calcium can limit IVUS imaging, but
its presence is also an important vessel characteristic in that
calcium is a limitation to needle penetration of the intima.
All of the cases in our series with prominent calcification
Fig 5. A, Total iliac occlusion recanalized and required
shows patent iliac after stenting.were successfully treated, and as such, we were not able todefine a pattern or amount of calcium that would preclude
re-entry with these devices.
The catheter does require 7F sheath access and will not
track in a sharply angulated fashion due to the 0.014-inch
monorail delivery system and the size and rigidity of the
transducer at the end of the catheter. This rigidity at the
end is an advantage in providing backup to the needle for
penetration of plaque or thickened intima at the time of
deployment. The catheter expense and availability of IVUS
may be the primary limitations to the widespread use of the
Pioneer.
The Outback catheter (Fig 2) had an initial limited release
by Lumend in November 2003. Its simple design and lack of
need for the IVUS console make it an attractive device. The
angled guide and needle hypo-tube are easily tracked in the
over-the-wire method using extra-support 0.014-inch wires.
The fluoroscopic imaging guidance is limited in the iliac
position owing to soft tissue attenuation of the image, partic-
ularly in obese patients. The imaging of the orientation of the
Outback device in the leg is very good.
The curved guide often resists positioning itself point-
ing at the true lumen and rides off the convexity of the
outside of the intima. Also, the needle deployment is less
controlled and, with the limited experience in our hands,
seemed to penetrate the intima less effectively; it routinely
took several attempts to penetrate. The newest design of
the Outback, the Outback LTD, was not used in this study,
lumen re-entry at the distal aorta. B, Final angiographytruebut has been used subsequently. This limited experience
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ment aspects of the Outback device have significantly im-
proved compared with the initial version (LuMend and its
Outback LTD catheter was acquired by Cordis Corpora-
tion in September, 2005).
Overall, both devices are very effective at their intended
use. It is our opinion that either of these devices can
significantly improve the acute procedural success of treat-
ing CTOs, particularly when treating TASD C and D iliac
lesions (Fig 5).
It is also our opinion that the accuracy of achieving
true lumen re-entry at the point desired is an advantage
that was not fully recognized before this experience with
the re-entry devices. This is true for both iliac and femoral
artery applications. Retrograde dissection to the distal aorta
in common iliac occlusions can put the inferior mesenteric
artery at risk of occlusion if the true lumen is entered above
its origin. Profunda collaterals to the femoral and popliteal
arteries can also be occluded if the dissection extends distal
to their reconstitution. Lipsitz et al7 reported that up to
47% of the collaterals distal to and 26% of the collaterals
proximal to subintimally treated CTOs of the lower ex-
tremity are lost after angioplasty.
Not extending the dissection from the external iliac
artery to an uninvolved common femoral artery, or the
superficial femoral artery to an uninvolved popliteal artery,
avoids the need for angioplasty or stenting, or both, of
these vessels that are known to have poorer long-term
patency rates. Additionally, limiting the extent of intimal
dissection and angioplasty in such cases may preserve sur-
gical options. For example, precise placement of the point
of re-entry into a reconstituted above-knee popliteal artery
may preserve the option of an above-knee femoropopliteal
bypass in the event of long-term failure of angioplasty or
stenting, or both, of a femoral occlusion.
The incidence of perforation seen in the treatment of
iliac occlusions in this study is high compared with other
series.8,9 Although there was concern that the use of nee-
dles andmanipulation for true lumen re-entry in these cases
might put the patients at risk of bleeding, the sites of
significant bleeding were not at the point of needle deploy-
ment, but rather in the middle of the chronic occlusions in
the common and external iliac arteries.
The need to use true lumen re-entry likely resulted in a
selection of patients that have more severe disease. This is
substantiated by the high complexity of the lesions treated in
this series as defined by their TASC classification. It is strongly
recommended that covered stent technology be available to
treat perforation when treating complex iliac CTOs.This series may indicate a rate of re-entry device use that
others would consider unnecessarily high; however, the
incidence of failure to re-enter the true lumen as a cause of
failure in treating CTOs is similar to other studies.1-3 It is
reasonable to assume that the high complexity of the lesion
morphology increased utilization rates of these devices.
Regardless, the rapid and precise nature of re-entry achieved
with these devices may also have resulted in a higher rate of
utilization of the devices as we became familiar with their
capability.
CONCLUSION
Our initial experience with true lumen re-entry cathe-
ters for treatment of CTOs suggests that the technical
success rate for endovascular treatment of these lesions is
enhanced by the use of these devices, particularly in the
complex iliac occlusions. Precision and ease of treatment
are important secondary benefits. We believe these devices
are essential tools in our toolbox for endovascular treat-
ment of patients with lower-extremity occlusive disease.
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